Burundi vs Ecuador: Average cost of multi drug-resistant tuberculosis treatment
Burundi
1,051 constant 2022 US$
in 2024
Ecuador
1,121 constant 2022 US$
in 2024
Burundi rank
45th
Ecuador rank
42nd
Average cost of multi drug-resistant tuberculosis treatment over time
- Burundi
- Ecuador
How they compare
Ecuador currently reports 1,121 constant 2022 US$ against 1,051 constant 2022 US$ in Burundi, a difference of 70 constant 2022 US$.
That makes Ecuador's figure about 1.1 times Burundi's.
The two have swapped places 1 time across 8 shared years of data; in 2017 it was Burundi ahead.
Burundi ranks 45th and Ecuador ranks 42nd of 92 countries.
Across the 2 decades both report, Burundi averaged higher in 1 and Ecuador in 1.
Head to head by decade
| Decade | Burundi | Ecuador | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 1,711 constant 2022 US$ | 754 constant 2022 US$ | 957 constant 2022 US$ | Burundi |
| 2020s | 1,020 constant 2022 US$ | 1,440 constant 2022 US$ | 419.8 constant 2022 US$ | Ecuador |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of multi drug-resistant tuberculosis treatment, Burundi or Ecuador?
- Ecuador, at 1,121 constant 2022 US$ against 1,051 constant 2022 US$ in Burundi as of 2024.
- What is the difference in average cost of multi drug-resistant tuberculosis treatment between Burundi and Ecuador?
- 70 constant 2022 US$, with Ecuador ahead.
- How many years of comparable data are there for Burundi and Ecuador?
- 8 years are reported by both, from 2017 to 2024.
- How do Burundi and Ecuador rank globally for average cost of multi drug-resistant tuberculosis treatment?
- Burundi ranks 45th and Ecuador ranks 42nd of 92 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of multi drug-resistant tuberculosis treatment. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting multidrug-resistant tuberculosis treatment, excluding buffer stock.